Neuroendocrine Tumors - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 150 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Neuroendocrine Tumors - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Neuroendocrine Tumors - Pipeline Review, H2 2014', provides an overview of the Neuroendocrine Tumors's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroendocrine Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neuroendocrine Tumors and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuroendocrine Tumors pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neuroendocrine Tumors Overview 9
Therapeutics Development 10
Pipeline Products for Neuroendocrine Tumors - Overview 10
Pipeline Products for Neuroendocrine Tumors - Comparative Analysis 11
Neuroendocrine Tumors - Therapeutics under Development by Companies 12
Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes 14
Neuroendocrine Tumors - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Neuroendocrine Tumors - Products under Development by Companies 18
Neuroendocrine Tumors - Products under Investigation by Universities/Institutes 19
Neuroendocrine Tumors - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Chiasma, Inc. 21
Delcath Systems, Inc. 22
DexTech Medical AB 23
Hutchison MediPharma Limited 24
Intezyne, Inc 25
Ipsen S.A. 26
Karyopharm Therapeutics, Inc. 27
Merck & Co., Inc. 28
Nobelpharma Co., Ltd. 29
Novartis AG 30
OctreoPharm Sciences GmbH 31
OXiGENE, Inc. 32
Progenics Pharmaceuticals, Inc. 33
Sompharmaceuticals S.A. 34
Tekmira Pharmaceuticals Corp. 35
Threshold Pharmaceuticals, Inc. 36
Neuroendocrine Tumors - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
DG-3173 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Edotreotide Labeled Yttrium 90 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
everolimus - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
evofosfamide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
fosbretabulin tromethamine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
G-02113 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ganitumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HMPL-012 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
IT-139 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
lanreotide acetate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
melphalan - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MK-2206 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
octreotide acetate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
OPS-201 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
panobinostat - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pasireotide LAR - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Peptides for Oncology - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
selinexor - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SNX-5422 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Somadex - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
streptozocin - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
TKM-PLK1 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Neuroendocrine Tumors - Recent Pipeline Updates 104
Neuroendocrine Tumors - Dormant Projects 138
Neuroendocrine Tumors - Discontinued Products 139
Neuroendocrine Tumors - Product Development Milestones 140
Featured News & Press Releases 140
Sep 17, 2014: Novartis presents oncology research advances with new data on Afinitor at ESMO 2014 140
Sep 17, 2014: OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors 140
Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe 141
Jul 16, 2014: New England Journal of Medicine Publishes Ipsen's Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors 142
Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors 143
Jan 17, 2014: Ipsen announces at ASCO GI that ELECT clinical trial of Somatuline in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint 144
Jan 14, 2014: Ipsen to set up its own US oncology team for Somatuline Depot Injection in neuroendocrine tumors 145
Oct 21, 2013: OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT in Pancreatic Neuroendocrine Tumor Model 146
Oct 15, 2013: Sompharmaceuticals receives CHF 100,000 award from the Swiss Foundation for Technological Innovation 147
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 147
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 150
Disclaimer 150

List of Tables
Number of Products under Development for Neuroendocrine Tumors, H2 2014 10
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Neuroendocrine Tumors - Pipeline by Amgen Inc., H2 2014 20
Neuroendocrine Tumors - Pipeline by Chiasma, Inc., H2 2014 21
Neuroendocrine Tumors - Pipeline by Delcath Systems, Inc., H2 2014 22
Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H2 2014 23
Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Limited, H2 2014 24
Neuroendocrine Tumors - Pipeline by Intezyne, Inc, H2 2014 25
Neuroendocrine Tumors - Pipeline by Ipsen S.A., H2 2014 26
Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 27
Neuroendocrine Tumors - Pipeline by Merck & Co., Inc., H2 2014 28
Neuroendocrine Tumors - Pipeline by Nobelpharma Co., Ltd., H2 2014 29
Neuroendocrine Tumors - Pipeline by Novartis AG, H2 2014 30
Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H2 2014 31
Neuroendocrine Tumors - Pipeline by OXiGENE, Inc., H2 2014 32
Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 33
Neuroendocrine Tumors - Pipeline by Sompharmaceuticals S.A., H2 2014 34
Neuroendocrine Tumors - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 35
Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 41
Number of Products by Stage and Route of Administration, H2 2014 43
Number of Products by Stage and Molecule Type, H2 2014 45
Neuroendocrine Tumors Therapeutics - Recent Pipeline Updates, H2 2014 104
Neuroendocrine Tumors - Dormant Projects, H2 2014 138
Neuroendocrine Tumors - Discontinued Products, H2 2014 139